Effectiveness and safety of recombinant human erythropoietin beta in maintaining common haemoglobin targets in routine clinical practice in Europe: The GAIN study

Current Medical Research and Opinion

Volumn 25, Issue 4, 2009, Pages 961-970

  Rath, Thomas ^a   Mactier, Robert A ^b   Weinreich, Thomas ^c   Scherhag, Armin W ^d,e,f  

^a Westpfalz Klinikum GmbH   (Germany)

^b STOBHILL HOSPITAL   (United Kingdom)

^c Clinical Center Villingen Schwenningen   (Germany)

^d F HOFFMANN LA ROCHE LTD   (Switzerland)

^e UNIVERSITY OF HEIDELBERG   (Germany)

^f F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

Anaemia; Chronic kidney disease; Epoetin beta; GAIN; Haemoglobin

Indexed keywords

ANTIANEMIC AGENT; ERYTHROPOIETIN ANTIBODY; HEMOGLOBIN; RECOMBINANT ERYTHROPOIETIN;

ADULT; ANEMIA; ARTICLE; CLINICAL PRACTICE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; DRUG SAFETY; EUROPE; FEMALE; GASTROINTESTINAL SYMPTOM; HEART DISEASE; HEMODIALYSIS; HEMOGLOBIN BLOOD LEVEL; HEMOGLOBIN DETERMINATION; HUMAN; INFECTION; INJECTION SITE PAIN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OBSERVATIONAL STUDY; PRACTICE GUIDELINE; PROSPECTIVE STUDY; RENAL REPLACEMENT THERAPY; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; VASCULAR DISEASE;

ADOLESCENT; ADULT; AGED; ANEMIA; ERYTHROPOIETIN, RECOMBINANT; EUROPE; HEMOGLOBINS; HUMANS; INJECTIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; KIDNEY FAILURE, CHRONIC; MIDDLE AGED; RENAL DIALYSIS; RETROSPECTIVE STUDIES; SAFETY; YOUNG ADULT;

EID: 67649354665     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007990902784459     Document Type: Article

References (20)

1. London GM. Left ventricular hypertrophy: why does it happen? Nephrol Dial Transplant 2003;18(Suppl 8):viii2-viii6
2. Pisoni RL, Bragg-Gresham JL, Young EW, et al. Anemia management and outcomes from 12 countries in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 2004;44:94-111 (Pubitemid 38880932)
3. KDOQI. KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease. Am J Kidney Dis 2006;47:11-145
4. Locatelli F, Aljama P, Barany P, et al. Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant 2004;19:1-47
5. KDOQI. KDOQI Clinical Practice Guideline and Clinical Practice Recommendations for anemia in chronic kidney disease: 2007 update of hemoglobin target. Am J Kidney Dis 2007;50:471-530
6. KDIGO Clinical Practice Guidelines. Recommendations on Haemoglobin Target. Available at: http://www.kdigo.org/nephrology-guideline-database/ guideline-target [last accessed: 21 January 2009]
7. Drueke TB, Locatelli F, Clyne N, et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 2006;355:2071-2084 (Pubitemid 44749316)
8. Muirhead N. A rationale for an individualized haemoglobin target. Nephrol Dial Transplant 2002;17:Suppl 6-7 (Pubitemid 34823542)
9. Singh AK, Szczech L, Tang KL, et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006;355:2085-2098 (Pubitemid 44749317)
10. Strippoli GF, Manno C, Schena FP, et al. Haemoglobin and haematocrit targets for the anaemia of chronic renal disease. Cochrane Database Syst Rev 2003;CD003967
11. Jacobs C, Frei D, Perkins AC. Results of the European Survey on Anaemia Management 2003 (ESAM 2003): current status of anaemia management in dialysis patients, factors affecting epoetin dosage and changes in anaemia management over the last 5 years. Nephrol Dial Transplant 2005;20:3-24
12. Locatelli F, Pisoni RL, Combe C, et al. Anaemia in haemodialysis patients of five European countries: association with morbidity and mortality in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant 2004;19:121-132 (Pubitemid 38072623)
13. Bennett CL, Luminari S, Nissenson AR, et al. Pure red-cell aplasia and epoetin therapy. N Engl J Med 2004;351:1403-1408 (Pubitemid 39288166)
14. Casadevall N, Nataf J, Viron B, et al. Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N Engl J Med 2002;346:469-475 (Pubitemid 34441737)
15. Grzeszczak W, Sulowicz W, Rutkowski B, et al. The efficacy and safety of once-weekly and once-fortnightly subcutaneous epoetin beta in peritoneal dialysis patients with chronic renal anaemia. Nephrol Dial Transplant 2005;20:936-944 (Pubitemid 40704030)
16. Locatelli F, Baldamus CA, Villa G, et al. Once-weekly compared with three-times-weekly subcutaneous epoetin beta: results from a randomized, multicenter, therapeutic-equivalence study. Am J Kidney Dis 2002;40:119-125 (Pubitemid 34701219)
17. Locatelli F. Once weekly treatment with epoetin-beta. Nephrol Dial Transplant 2005;20:Suppl 6-30
18. Weiss LG, Clyne N, Divino FJ, et al. The efficacy of once weekly compared with two or three times weekly subcutaneous epoetin beta: results from a randomized controlled multicentre trial. Swedish Study Group. Nephrol Dial Transplant 2000;15:2014-2019
19. Gross J, Moller R, Henke W, et al. Detection of anti-EPO antibodies in human sera by a bridging ELISA is much more sensitive when coating biotinylated rhEPO to streptavidin rather than using direct coating of rhEPO. J Immunol Methods 2006;313:176-182
20. Kaufman JS, Reda DJ, Fye CL, et al. Subcutaneous compared with intravenous epoetin in patients receiving hemodialysis. Department of Veterans Affairs Cooperative Study Group on Erythropoietin in Hemodialysis Patients. N Engl J Med 1998;339:578-583